Stockscreener 앱 받기
61.65
2.78%
1.67
시간 외 거래:
61.60
-0.05
-0.08%
전일 마감가:
$59.98
열려 있는:
$60.24
하루 거래량:
1.60M
Relative Volume:
0.50
시가총액:
$8.03B
수익:
$638.78M
순이익/손실:
$-22.66M
주가수익비율:
-353.50
EPS:
-0.1744
순현금흐름:
$122.18M
1주 성능:
-4.06%
1개월 성능:
+30.42%
6개월 성능:
+166.42%
1년 성능:
+361.11%
1일 변동 폭
$59.41
$63.49
1주일 범위
$58.70
$65.74
52주 변동 폭
$11.16
$66.94
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
61.65 | 8.32B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
280.72 | 40.70B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
60.25 | 11.78B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
61.94 | 12.03B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
98.54 | 8.72B | 1.34B | 230.70M | 440.96M | 2.6695 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | 개시 | Piper Sandler | Neutral |
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade) (TXG) - Seeking Alpha
Federal Circuit Upholds PTAB Obviousness Rulings Against Single Cell Sequencing Patents - IPWatchdog.com
10x Genomics Gains as Investors Extend Post-Earnings Rally on Atera Demand - Quiver Quantitative
10x Genomics’ Bid to Revive Patents Rejected by Federal Circuit - Bloomberg Law News
10x Genomics (NASDAQ:TXG) Reaches New 52-Week HighWhat's Next? - MarketBeat
10x Genomics stock hits 52-week high at $60.73 By Investing.com - Investing.com Australia
10x Genomics stock hits 52-week high at $60.73 - Investing.com
Bank of America Corp DE Has $20.48 Million Position in 10x Genomics $TXG - MarketBeat
Director Sarah Teichmann Sells 7,551 Shares of 10x Genomics Inc (TXG) - GuruFocus
A Look at 10x Genomics Inc (TXG) After 3.4% Gain -- GF Value $18 - GuruFocus
10x Genomics Inc (TXG) (Q2 2026) Earnings Call Highlights: Atera Launch Drives Record Demand Amidst Transition - GuruFocus
10x Genomics (NASDAQ: TXG) director sells under 10b5-1 plan - Stock Titan
7 Best Genomics Stocks for 2026 and How to Invest - The Motley Fool
symbol__ Stock Quote Price and Forecast - CNN
10x Genomics (TXG) Dips 3.5% to $56.09 as Support at $53.29 Comes Into ViewTrend Reversal Picks - Vinanet
5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call - Yahoo Finance
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital By Investing.com - Investing.com Canada
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital - Investing.com
A Look at 10x Genomics Inc (TXG) After 3.6% Decline -- GF Value $18.38 vs Price $56.09 - GuruFocus
TXG (TXG) insider schedules sale of common stock and notes prior sale - Stock Titan
ARK Investment Management (TXG) reports 10.0M-share position in 10x Genomics - Stock Titan
10x Genomics, Inc.: Financial Data Forecasts Estimates and Expectations | TXG | US88025U1097 - marketscreener.com
10x Genomics director John Stuelpnagel sells $1.15m in shares - Investing.com
10x Genomics director John Stuelpnagel sells $1.15m in shares By Investing.com - Investing.com Australia
10x Genomics Director John R. Stuelpnagel Sells 20,000 Shares in August 2026 SEC Filing - Kalkine Media
Insider Selling: 10x Genomics (NASDAQ:TXG) Director Sells 20,000 Shares of Stock - MarketBeat
10x Genomics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
10x Genomics (TXG) director John Stuelpnagel sells 20,000 shares in August 11 trades - Stock Titan
Why 10x Genomics (TXG) Is Up 21.7% After Raising 2026 Outlook Despite Q2 Revenue Drop - simplywall.st
10x Genomics $TXG Shares Acquired by Sei Investments Co. - MarketBeat
US$49.54That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results - webull.com
10x Genomics, Inc. SEC Filing (Aug 11, 2026) - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: Navigating the High Valuation and Market Dynamics - DirectorsTalk Interviews
Is 10x Genomics Inc (TXG) Overvalued After 12.3% Rally? GF Value - GuruFocus
10x Genomics, Inc. (TXG) stock price, news, quote and history - Yahoo Finance UK
10x Genomics (NASDAQ:TXG) Trading Up 7.1%Time to Buy? - MarketBeat
TXG Stock Jumps As Earnings Beat Triggers Analyst Upgrades - StocksToTrade
10X GENOMICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $60 FROM $50 - Bitget
10x Genomics Stock Jumps As Analysts Hike Price Targets - timothysykes.com
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of 10x Genomics Inc Class A – BMV:TXG - TradingView
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
TXG Jumps As 10x Genomics Price Targets Surge After Q2 Beat - timothysykes.com
10X Genomics Inc (TXG) Stock News Today - tradingkey.com
10x Genomics, Inc. Stock 12‑Month Price Target Raised to $47.23, Implies 4% Upside - TradingView
10x Genomics Q2 Earnings Call Highlights - MarketBeat
10x Genomics stock hits 52-week high at 50.36 USD - Investing.com
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up - TradingView
10x Genomics: Atera Sees ‘Extraordinary’ Customer Response As Multiomics Strategy Expands - Pulse 2.0
10X GENOMICS, INC. : JEFFERIES RAISES TARGET PRICE TO $53 FROM $40 - Moomoo
10x Genomics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.59%
0.16%
자본화:
|
볼륨(24시간):